ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer

• Published in: BMC cancer Vol. 23; no. 1; p. 440
• Main Authors: Yao, Litong, Li, Yuwei, Li, Siyuan, Wang, Mozhi, Cao, Hongyi, Xu, Ling, Xu, Yingying
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.05.2023; BioMed Central; BMC
• Subjects: Analysis; ARHGAP39; B cells; Biological markers; Biomarker; Biomarkers; Breast cancer; Breast Neoplasms - genetics; Cancer; Cancer therapies; Carcinogenesis; Care and treatment; CD4 antigen; CD8 antigen; Cell growth; Cell proliferation; Cholecystokinin; Datasets; Female; Gene expression; Gene set enrichment analysis; Genetic aspects; Genomes; Genomics; Genotypes; Health aspects; Humans; Immune infiltration; Immune system; Infiltration; Leukocyte migration; Lymphocytes; Lymphocytes T; Macrophages; Medical prognosis; Metastases; Prognosis; Proteins; Proteomics; Software packages; Survival analysis; T cells; Therapeutic targets; Tumor cell lines; Tumorigenesis; China; Biomarker; ARHGAP39; Breast cancer; Prognosis; Immune infiltration
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-10904-4

Current studies on the role of ARHGAP39 mainly focused on its effect on neurodevelopment. However, there are few studies on the comprehensive analysis of ARHGAP39 in breast cancer. ARHGAP39 expression level was analyzed based on the Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression Project (GTEx), and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database and validated by qPCR in various cell lines and tumor tissues. The prognostic value was analyzed using Kaplan-Meier curve analysis. CCK-8 and transwell assays were conducted to identify the biological function of ARHGAP39 in tumorigenesis. Signaling pathways related to ARHGAP39 expression were identified by the GO and KEGG enrichment analysis and gene set enrichment analysis (GSEA). The correlations between ARHGAP39 and cancer immune infiltrates were investigated via TIMER, CIBERSORT, ESTIMATE and tumor-immune system interactions database (TISIDB). ARHGAP39 was overexpressed in breast cancer and associated with poor survival outcomes. In vitro experiments revealed that ARHGAP39 could facilitate the proliferation, migration, and invasion capability of breast cancer cells. GSEA analysis showed that the main enrichment pathways of ARHGAP39 was immunity-related pathways. Considering the immune infiltration level, ARHGAP39 was negatively associated with infiltrating levels of CD8 + T cell and macrophage, and positively associated with CD4 + T cell. Furthermore, ARHGAP39 was significantly negatively correlated with immune score, stromal score, and ESTIMATE score. Our findings suggested that ARHGAP39 can be used as a potential therapeutic target and prognostic biomarker in breast cancer. ARHGAP39 was indeed a determinant factor of immune infiltration.